|
|
|
|
|
1
|
Therapeutic Clinical Intelligence - Rheumatoid Arthritis |
Jan 2009 |
$2,300.00 |
|
Rheumatoid arthritis (RA) is a chronic and debilitating autoimmune disease that affects an estimated 2 million people in the United States and an estimated 20 million individuals worldwide. The RA treatment market has undergone significant
more...
Published by: Austin Research Group
| Search inside this report |
|
|
2
|
Therapeutic Area Clinical Intelligence: Type-2 Diabetes Pipeline |
Jun 2008 |
$4,500.00 |
|
Diabetes affects more than an estimated 18 million people in the United States and approximately 194 million adults worldwide. The World Health Organization projects that the number of people with diabetes will double to 366
more...
Published by: Austin Research Group
| Search inside this report |
|
|
3
|
Trial TRAX Multiple Sclerosis Clinical Trial Monitoring Brief |
Oct 2007 |
$1,000.00 |
|
The Multiple Sclerosis (MS) therapeutic market will experience a significant shift in power in the next five years. The current market leaders, Interferons and Copaxone, could lose their dominance to novel orally formulated and biologic
more...
Published by: Austin Research Group
| Search inside this report |
|
|
4
|
Alzheimer's Disease Clinical Trial Monitoring Brief |
Oct 2007 |
$700.00 |
|
Austin Research Group’s Trial TRAX Clinical Intelligence Monitoring series provides detailed compilations and analysis of ongoing clinical studies within a specific therapeutic area or indication. Additionally, the Trial TRAX briefs contain synthesized background information on
more...
Published by: Austin Research Group
|
|
|
5
|
Rheumatoid Arthritis Clinical Trial Monitoring Brief |
Aug 2007 |
$600.00 |
|
Austin Research Group’s Trial TRAX Clinical Intelligence Monitoring series provides detailed compilations and analysis of ongoing clinical studies within a specific therapeutic area or indication. Additionally, the Trial TRAX briefs contain synthesized background information on
more...
Published by: Austin Research Group
|
|
|
6
|
Therapeutic Clinical Intelligence - Psoriasis |
Jul 2007 |
$900.00 |
|
The world-wide market for Psoriasis therapeutics is estimated to be valued at $1-$3 billion annually. There are currently only 3 biologic competitors vying for share of this market. The Anti-TNF-a monoclonal antibodies—Enbrel, Humira, and Remicade—currently
more...
Published by: Austin Research Group
| Search inside this report |
|
|
7
|
Therapeutic Clinical Intelligence-Multiple Sclerosis |
Apr 2007 |
$4,100.00 |
|
Competitive intelligence on the clinical trials of products on the market and in development for Multiple Sclerosis
Scope of Report
The scope of this report will primarily concentrate on the R&D competitive landscape for
more...
Published by: Austin Research Group
|
|
|
8
|
Therapeutic Clinical Intelligence-Inflammatory Bowel Disease |
Mar 2007 |
$3,100.00 |
|
Crohn¡¦s Disease Market
In 2007, Remicade (infliximab/Anti-TNF-fÑ), the current market leader in the treatment of moderate-to-severe Crohn¡¦s Disease (CD), is expected to experience fierce challenges for patient share from 2-3 new Anti-TNF class competitors; Humira,
more...
Published by: Austin Research Group
| Search inside this report |
|
|
|
|
|
0 items
